51985-95-6Relevant articles and documents
PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE
-
Page/Page column 50; 75-76, (2019/11/04)
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13
Taylor, Steven J.,Abeywardane, Asitha,Liang, Shuang,Muegge, Ingo,Padyana, Anil K.,Xiong, Zhaoming,Hill-Drzewi, Melissa,Farmer, Bennett,Li, Xiang,Collins, Brandon,Li, John Xiang,Heim-Riether, Alexander,Proudfoot, John,Zhang, Qiang,Goldberg, Daniel,Zuvela-Jelaska, Ljiljana,Zaher, Hani,Li, Jun,Farrow, Neil A.
experimental part, p. 8174 - 8187 (2012/01/13)
Matrix metalloproteases (MMPs) play an important role in cartilage homeostasis under both normal and inflamed disease states and, thus, have become attractive targets for the treatment of arthritic diseases. Herein, we describe the identification of a pot
Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors
Liu, Mei,Xin, Zhili,Clampit, Jill E.,Wang, Sanyi,Gum, Rebecca J.,Haasch, Deanna L.,Trevillyan, James M.,Abad-Zapatero, Cele,Fry, Elizabeth H.,Sham, Hing L.,Liu, Gang
, p. 2590 - 2594 (2007/10/03)
A novel class of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as c-Jun-N-terminal kinase (JNK) inhibitors is described. These compounds were synthesized via the condensation of 2-nitrobenzaldehydes and hydroxypyrazoles. The structure-activity relationships (SAR) and kinase selectivity profile of the inhibitors are also discussed. Compound 16 was identified as a potent JNK inhibitor with good cellular potency.